Biogen ventures into ophthalmology with $1-bn AGTC tie-up 04 July 2015 Biogen Idec to pay Elan Corp $3.25 bn plus for full rights of multiple sclerosis drug Tysabri 06 February 2013 Biogen assumes full development responsibilities for hemophilia therapy 18 February 2010 Facet Biotech spurns Biogen's buyout bid 09 September 2009 Biogen Idec up for sale after Icahn offer 13 October 2007 Nicholas Piramal enters into alliance with Biogen Idec, USA 02 December 2003
Biogen Idec to pay Elan Corp $3.25 bn plus for full rights of multiple sclerosis drug Tysabri 06 February 2013
